Dr. Janet S. Rader and her current lab staff, Marissa Iden, PhD and Shirng-Wern Tsaih, ScD, most recently published their findings in the British Journal of Cancer – “Multi-Omics Mapping of Human Papillomavirus Integration Sites Illuminates Novel Cervical Cancer Target Genes.”
Invasive cervical cancer kills nearly 311,000 women each year worldwide with an estimated 50% increase in deaths by 2040. Women with advanced or recurrent cervical cancer often develop resistance to current chemotherapy options, and >90% die within 2 years. Thus, identification and characterization of novel, clinically actionable target genes remains a crucial avenue of research for development of
more effective therapeutic approaches for women with cervical cancer. Our recent study published in the British Journal of Cancer describes a workflow for identification and prioritization of putative cervical cancer target genes from tumor HPV integration signatures.
Integration of the human papillomavirus (HPV) into the host genome is a major driver of cervical cancer. In this publication, we develop and test a pipeline that uses features of HPV integration events to identify and characterize potential novel therapeutic targets for treating women with cervical cancer.
